Comment by
lscfa on Apr 23, 2021 10:53am
Interviewer asked what is it that investors are not getting? Part of the answer is confusion on whether Tetra is a cannabis stock or a biotech stock. I would add there is confusion on what is difference between CAUMZ and QIXLEEF. Are they both synthetic cannabis drugs? If so, why is Aphria the manufacturer? Does Aphria make synthetic cannabinoids?
Comment by
timetoscorebig on Apr 23, 2021 10:55am
This post has been removed in accordance with Community Policy
Comment by
resistnothing on Apr 23, 2021 3:54pm
Will be a long while yet until we find out whether the drug works. He mentioned 30 days then changed it to 30 to 90 days!!!
Comment by
lscfa on Apr 23, 2021 5:04pm
More confusion: CAUMZ is a synthetic drug and QIXLEEF is a plant-based drug. Why? QIXLEEF has a fixed ratio of cbd:thc. What is CAUMZ mimicking as a synthetic? Why not make QIXLEEF synthetically to ensure a fixed ratio? Can a grower (Aphria) really guarantee consistency with tight tolerances?
Comment by
MiningGospel on Apr 23, 2021 5:16pm
There's something called the Entourage effect, where CBD +THC + Terpenes work in conjunction with each other to help with pain relief. Rafi Mechoulum has done a lot of work in this field
Comment by
lscfa on Apr 23, 2021 8:17pm
The co. is spending millions to prove that inhaled cannabis is better than opioids. If successful why would doctors prescribe QIXLEEF, especially if it is priced a lot higher than other medical cannabis? There's a risk doctors will piggyback off the QIXLEEF study and write their patients a note for some other medical cannabis with a similar THC:CBD ratio.
Comment by
WebSwinger on Apr 23, 2021 10:09pm
With QIXLEEF, I'm sure it can be covered under health insurance, so patiants get it for cheaper or for free in some cases. As for the other comments, tetra should have synthetic and non synthetic drugs. Diversity is good for many reasons of which i am to busy to list.
Comment by
MiningGospel on Apr 24, 2021 1:21am
This is completely incorrect. There is a pharmaceutical standard to achieve. Contaminants are a huge deal with pressed flower and TBP has dealt with this already. And insurance providers would cover the cost of the drug so no, your scenario is highly unethical and improbable